Compare American Water Works Company Inc (AWK) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Water Works Company Inc vs Summit Therapeutics Inc — how do they compare? American Water Works Company Inc trades at $136.06 (market cap $26.92B), while Summit Therapeutics Inc trades at $15.35 (market cap $11.87B). The key difference: American Water Works Company Inc is far larger — about 2.3× Summit Therapeutics Inc's market cap, and American Water Works Company Inc pays a 2.64% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AWK | SMMT | |
|---|---|---|
Market Cap | $26.92B | $11.87B |
Sector | Utilities | Health |
52-Week High | $146.20 | $28.25 |
52-Week Low | $121.13 | $12.55 |
Enterprise Value | $42.78B | $11.20B |
Dividend Yield | 2.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AWK trades at $135.31, up 0.36% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 EPS of $1.61, beating estimates, while Q1 and Q4 2025 missed. Revenue grew to $5.14B in 2025 with a 21.35% net margin. Analyst consensus is mixed with 14 Buy, 14 Hold, and 2 Sell ratings, targeting $139.83. Recent news highlights operational excellence awards and customer base expansion through acquisitions.
Outlook remains stable with consistent dividend payments and guided EPS growth. Risks include rising debt levels and regulatory pressures. The stock offers steady income and moderate growth potential, but investors should monitor execution on earnings targets and capital expenditure efficiency.
Summit Therapeutics (SMMT) trades at $13.96, up 3.1% today, but faces bearish technical signals with negative ROE of -192.5% and net income of -$1.08B for 2025. The company's key catalyst is the FDA review of ivonescimab with a November 2026 decision, supported by expanded clinical trials in bladder and kidney cancer. Cash flow remains dependent on financing activities, with operating cash flow negative at -$323M in 2025.
Investment outlook hinges on ivonescimab's FDA approval, with analyst consensus target at $27.90 offering significant upside. However, high execution risk, ongoing losses, and fiduciary investigations present substantial downside. The stock represents a high-risk biotech speculation with binary outcomes based on regulatory success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
